The government will spend $30 million on BPA research in humans and animals, to take place over 18 to 24 months, health officials said at a news briefing on Friday.

Dr. Linda Birnbaum, director of the National Institute of Environmental Health Sciences, said the research would involve potential effects on behavior, obesity, diabetes, reproductive disorders, cancer, asthma, heart disease and effects that could be carried from one generation to the next.

Activists on both sides of the passionately debated issue said they were disappointed in the government’s action. The American Chemical Council, which represents companies that make and use BPA, issued a statement saying BPA was safe, praising the health agencies as confirming that there was no proof of harm to people by it, but also saying, “We are disappointed that some of the recommendations are likely to worry consumers and are not well founded.”

Diana Zuckerman, president of the National Research Center for Women and Families, said the F.D.A. had not gone far enough, because its recommendations put the responsibility on families and not on companies making products containing BPA. In addition, Ms. Zuckerman said, the focus on safety should not be limited to children, because studies have linked the chemicals to heart and liver disease and other problems in adults.

Government evaluations of BPA have had a contentious history. The drug agency wrote a draft report calling it safe in 2008. But shortly after that, the National Toxicology Program, part of the National Institutes of Health, said BPA was cause for “some concern,” citing the same issues that the drug agency is now agreeing to: potential effects on the brain, behavior and prostate in fetuses, infants and children.

Then the drug agency asked an independent panel of scientific advisers to review its draft report, and the panel gave it a scathing review. It accused the F.D.A. of ignoring important evidence and giving consumers a false sense of security about the chemical. The drug agency promised to reconsider BPA, and the announcement on Friday fulfilled that pledge.

“We are for the first time saying we believe there is some concern about the substance’s safety, and we’ve closed the gap between N.I.H. and F.D.A.,” Dr. Sharfstein of the F.D.A. said in an interview.